Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093) and raises target price by 9.1% to HKD 12, while keeping profit forecasts for 2025 and 2026 at CNY 4.76 billion and CNY 5.35 billion, respectively, and introducing a forecast of CNY 5.70 billion for 2027 [1] Group 1 - CSPC Pharmaceutical has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of eight innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [2] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative milestone payments for development and sales, with Giant Biologics (a subsidiary of New Horizon (300765)) entitled to 35% of the upfront payment and subsequent milestone payments [2] Group 2 - The company is betting on long-acting peptide drugs to compete in the weight loss and metabolic market, with its drug SYH2082 progressing to Phase I clinical trials as a monthly injection GLP1R/GIP agonist [3] - Pfizer's acquisition of Metsera for USD 10 billion highlights the competitive landscape, as Metsera's proprietary NuSH platform enables a long half-life for its weight loss drug MET-097 [3] Group 3 - CSPC has achieved significant external licensing agreements in 2025, including USD 120 million for oral small molecule GLP-1, USD 110 million for the AstraZeneca strategic partnership, and USD 15 million for ROR1ADC, indicating a trend towards regular income from external licensing [4] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, which are expected to lead to further successful licensing and milestone revenue recognition [4]

Core Viewpoint - CICC maintains a "outperform" rating for CSPC Pharmaceutical Group (01093) and raises the target price by 9.1% to HKD 12, considering the continued success of external licensing agreements [1] Group 1: Licensing Agreements and Financial Projections - CSPC has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of 8 innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [1] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative development and sales milestone payments [1] - The company maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.35 billion, respectively, and introduces a forecast of RMB 5.70 billion for 2027 [1] Group 2: Market Position and Competitive Landscape - The company is positioned in the long-acting peptide drug market, competing with major players like Pfizer, which acquired Metsera for USD 10 billion to enhance its weight loss drug portfolio [2] - CSPC's SYH2082 is advancing to Phase I clinical trials as a long-acting GLP1R/GIP agonist, with expectations for favorable efficacy and safety data [2] Group 3: Revenue Generation from Licensing - In 2025, the company has already achieved external licensing revenues from various projects, including USD 120 million from oral small molecule GLP-1 and USD 110 million from the AstraZeneca strategic collaboration [3] - The company has a pipeline of innovative assets, including EGFR ADC and SiRNA series, which are expected to lead to further successful licensing agreements and milestone revenue recognition [3]

Company Updates - The company announced a research and development collaboration and licensing agreement with AstraZeneca for eight innovative long-acting peptide drug projects, including SYH2082 and three preclinical molecules, with an additional four projects under collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in development and sales milestone payments, with a subsidiary entitled to receive 35% of the upfront payment and subsequent milestone payments and royalties [1] Industry Insights - The collaboration marks a significant milestone for Chinese innovative drug licensing abroad, as multinational corporations (MNCs) are betting on long-acting peptide drugs to compete in the weight loss and metabolic market [1] - The company’s SYH2082 is a long-acting GLP1R/GIP agonist progressing to Phase I clinical trials, with expectations for more favorable efficacy and safety data [1] Revenue Generation - The company has achieved external licensing agreements in 2025, including $120 million for oral small molecule GLP-1, $110 million for the AstraZeneca collaboration, and $15 million for other projects, indicating a potential for regular income from licensing [2] - The company has a pipeline of innovative assets, including EGFR ADC/SiRNA series, which are expected to lead to further licensing agreements and milestone revenue recognition [2] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 is maintained at 4.76 billion yuan and 5.35 billion yuan, with an introduction of a 2027 forecast of 5.70 billion yuan [2] - The current stock price corresponds to a price-to-earnings ratio of 18.7 and 17.1 times for 2026 and 2027, respectively, with a target price adjustment of 9.1% to HKD 12.00, implying a 25% upside potential [2]